Circulogene Unveils Advanced OncoGenDx Tissue Assay for Oncology

Circulogene Unveils Innovative OncoGenDx Tissue Assay

Circulogene has revolutionized the field of precision oncology with the launch of its groundbreaking assay, OncoGenDx. This comprehensive genomic profiling (CGP) test is designed to provide essential insights into a variety of solid tumors. By broadening its testing capabilities, Circulogene aims to deliver advanced solutions that empower clinicians in making informed treatment choices.

Transforming Diagnostic Approaches in Oncology

Aligned with Circulogene's vision, OncoGenDx enhances the existing offerings, which include OncoGenLDx—the only plasma-based test that delivers PD-L1 expression results. Furthermore, the LungLifeAI solution aids in the risk assessment of incidental lung nodules, bringing a thorough understanding into a clinician's decision-making process. The launch of OncoGenDx underlines the company's dedication to advancing solid tumor analysis through innovative and practical testing methodologies.

Streamlined Testing for Clinicians

The OncoGenDx assay has been meticulously designed for simplicity and speed. Clinicians can submit orders directly to Circulogene, with the added convenience of pathology retrieval managed by the Client Services team. Patients can expect results delivered in a combined report format, typically within 10–14 days. This quick turnaround fosters timely clinical decision-making, ultimately benefiting patient outcomes.

Robust Genomic Analysis Features

OncoGenDx offers significant technological advancements by utilizing next-generation sequencing (NGS) techniques. The assay provides a molecular analysis of formalin-fixed paraffin-embedded (FFPE) tumor tissues across varying types of solid tumors. With the ability to evaluate 335 DNA genes and 72 RNA genes, it can identify key genomic alterations such as single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), and structural variants (SVs). Moreover, it identifies actionable fusions, making it a critical tool for enhancing cancer treatment strategies.

Supporting Oncology Decision-Making

One of the most notable aspects of the OncoGenDx assay is its reporting of complex genomic signatures. These include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD). These factors are invaluable for guiding both targeted therapies and immunotherapies, paving the way for personalized patient care. Additionally, the option for PD-L1 IHC (22C3 clone) testing is available, further augmenting the assay's capabilities.

About Circulogene and Its Vision

Circulogene stands at the forefront of precision oncology and strives to deliver molecular diagnostics that are practical and closely aligned with clinical workflows. The company’s headquarters in Pensacola serves as a hub for innovation, yielding a product lineup that includes OncoGenLDx and LungLifeAI, ensuring a comprehensive diagnostic toolset for clinicians.

Circulogene remains committed to evolving its portfolio to meet the dynamic needs of healthcare providers. The introduction of the OncoGenDx assay marks a new chapter in the company’s mission to bridge the gap between advanced genomic science and everyday clinical practice.

Frequently Asked Questions

What is OncoGenDx?

OncoGenDx is a comprehensive genomic profiling assay developed by Circulogene for analyzing solid tumors.

How does OncoGenDx benefit clinicians?

This assay provides valuable molecular data that aids clinicians in making timely and informed treatment decisions.

What types of genomic alterations can OncoGenDx identify?

It identifies single nucleotide variants (SNVs), insertions/deletions (Indels), and other significant structural variations.

What are complex genomic signatures reported by OncoGenDx?

Complex signatures include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD).

Where is Circulogene located?

Circulogene is based in Pensacola, Florida, where it develops innovative oncology solutions.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.